Until 1982, the only insulin in a patient's syringe came from pig and cattle pancreases.

That year regulators approved insulin made by E. coli carrying the human insulin gene.

A therapy approved in 2023 disables one spot in the patient's own DNA and leaves no foreign gene behind.

Both are genetic engineering, so what separates them?